Search peptides, terms, sources/

UK peptide evidence reference

The periodic table
of peptides

A free, source-led reference to peptides for UK readers. Every finding is graded for evidence strength and every claim links to a public source.

34peptides12research areas161sourcesSite last updated Nov 2026

Browse all peptidesBrowse by research areaBrowse by UK status

34 of 34 peptides
01 Metabolic and incretin02 Growth hormone axis03 Brain and mood04 Melanocortin05 Hormonal signalling06 Immune and longevity07 Repair and regeneration 05CgCagrilintide. UK status: Not licensed in the UK. Best recorded finding: moderate evidence. 16LrLiraglutide. UK status: Licensed UK medicine. Best recorded finding: moderate evidence. 17MzMazdutide. UK status: Not licensed in the UK. Best recorded finding: strong evidence. 22RtRetatrutide. UK status: Not licensed in the UK. Best recorded finding: moderate evidence. 24SmSemaglutide. UK status: Licensed UK medicine. Best recorded finding: strong evidence. 28SvSurvodutide. UK status: Not licensed in the UK. Best recorded finding: strong evidence. 34TzTirzepatide. UK status: Licensed UK medicine. Best recorded finding: strong evidence. 03AoAOD‑9604. UK status: Not licensed in the UK. Best recorded finding: moderate evidence. 06CjCJC‑1295. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 10G2GHRP‑2. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 11G6GHRP‑6. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 12HxHexarelin. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 13IpIpamorelin. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 26SrSermorelin. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 31TsTesamorelin. UK status: Not licensed in the UK. Best recorded finding: strong evidence. 23SlSelank. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 25SxSemax. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 02AfAfamelanotide. UK status: Licensed UK medicine. Best recorded finding: moderate evidence. 18MtMelanotan II. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 21PtPT‑141. UK status: Not licensed in the UK. Best recorded finding: strong evidence. 27SeSetmelanotide. UK status: Licensed UK medicine. Best recorded finding: moderate evidence. 01AbAbaloparatide. UK status: Licensed UK medicine. Best recorded finding: strong evidence. 14KsKisspeptin. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 20OxOxytocin. UK status: Licensed for a different use. Best recorded finding: limited evidence. 30TpTeriparatide. UK status: Licensed UK medicine. Best recorded finding: strong evidence. 07ElElamipretide. UK status: Not licensed in the UK. Best recorded finding: preliminary evidence. 08EpEpithalon. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 15KvKPV. UK status: Not licensed in the UK. Best recorded finding: preliminary evidence. 19McMOTS‑c. UK status: Not licensed in the UK. Best recorded finding: preliminary evidence. 32TaThymosin Alpha‑1. UK status: Not licensed in the UK. Best recorded finding: moderate evidence. 04BpBPC‑157. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 09GkGHK‑Cu. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 29TbTB‑500. UK status: Not licensed in the UK. Best recorded finding: limited evidence. 33T4Thymosin beta‑4. UK status: Not licensed in the UK. Best recorded finding: limited evidence.

Bars = evidence grade of the best single recorded finding: Preliminary Limited Moderate StrongHow grading works

How PeptGuru works: every claim cites a source

  1. Sourced. Each finding links to the study, trial or regulator document behind it. Nothing is stated without a source you can open.
  2. Graded. Findings are graded Strong, Moderate, Limited or Preliminary, by the kind of study and how many people it involved.
  3. Dated. UK status and evidence carry the date they were last checked, and every change is logged in public.
Read the method

How to read a profile

Every profile uses the same three labels. Each one answers a different question.

Study type

Shows what kind of study found a result: human trial, human observational, animal or laboratory.

  • Human trials
  • Human observational
  • Animal studies
  • Lab studies
How study types are ranked

Evidence strength

Shows how strong the study evidence is behind each recorded finding, in four levels from Strong to Preliminary. It grades the finding, not the medicine.

  • Strong
  • Moderate
  • Limited
  • Preliminary
How strength is graded

UK status

Shows a peptide's UK licensing position on a stated date. A record of regulation only.

  • Licensed UK medicine
  • Licensed for a different use
  • Not licensed in the UK
What the labels mean

Recently updated

  • PT-141 (Bremelanotide)

    UK status now cites an MHRA Products database search (no UK authorisation found). An unsourced statement about the reason was removed.

    Regulatory update
  • Liraglutide

    The safety source is now the official UK product information (Summary of Product Characteristics) for liraglutide's weight-management product, replacing an uncited monograph reference.

    Correction
  • Liraglutide

    The SCALE trial reference now carries its DOI and PubMed ID (Pi-Sunyer et al., NEJM 2015).

    Correction
  • Tirzepatide

    The SUMMIT trial reference now carries its DOI and PubMed ID (Packer et al., NEJM 2025).

    Correction
  • AOD-9604

    A finding based on an unidentifiable early-phase source was removed, as was an unsourced toxicology statement. The Phase IIb result is now cited to its 2005 conference record and a 2026 peer-reviewed review.

    Correction

All changes

Free. No ads. No sign-up. Every claim cites a source. Run voluntarily by Astute Management for research and education. About Corrections

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.